CoChat
Sign Up
Cited by 82Nanoparticle-Based Drug DeliveryArtificial Intelligence in Healthcare and EducationComputational Drug Discovery Methods

Enhancing Clinical Translation of Cancer Using Nanoinformatics

Open access
Soltani, Madjid, Moradi Kashkooli, Farshad, Souri, Mohammad, Zare Harofte, Samaneh, Harati, Tina, Khadem, Atefeh, Haeri Pour, Mohammad, Raahemifar, Kaamran·2021·Cancers
DOI 10.3390/cancers13102481PMC PMC8161319
Open this paper in CoChat — free accountOpen PDF

Abstract

Application of drugs in high doses has been required due to the limitations of no specificity, short circulation half-lives, as well as low bioavailability and solubility. Higher toxicity is the result of high dosage administration of drug molecules that increase the side effects of the drugs. Recently, nanomedicine, that is the utilization of nanotechnology in healthcare with clinical applications, has made many advancements in the areas of cancer diagnosis and therapy. To overcome the challenge of patient-specificity as well as time- and dose-dependency of drug administration, artificial intelligence (AI) can be significantly beneficial for optimization of nanomedicine and combinatorial nanotherapy. AI has become a tool for researchers to manage complicated and big data, ranging from achieving complementary results to routine statistical analyses. AI enhances the prediction precision of treatment impact in cancer patients and specify estimation outcomes. Application of AI in nanotechnology leads to a new field of study, i.e., nanoinformatics. Besides, AI can be coupled with nanorobots, as an emerging technology, to develop targeted drug delivery systems. Furthermore, by the advancements in the nanomedicine field, AI-based combination therapy can facilitate the understanding of diagnosis and therapy of the cancer patients. The main objectives of this review are to discuss the current developments, possibilities, and future visions in naoinformatics, for providing more effective treatment for cancer patients.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13102481

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tissue damage and lesions in cancer sites make a pro-inflammatory environment that recruits various cells such as mesenchymal stem cells.

    “Tissue damage and lesions in cancer sites make a pro-inflammatory environment that recruits various cells such as MSCs [74–76].”

    From Mesenchymal stromal cells in bone marrow niche of patients with multiple myeloma: a double-edged sword (2025) · cites this paper as [76]

    Section 3.2 discusses inflammatory-cell activation in response to nanoparticles, not inflammation caused by tissue damage or lesions at cancer sites. Searches for mesenchymal stem cells, MSC recruitment, and a pro-inflammatory tumor environment found no passage addressing the claimed mechanism. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 98 · Cited by 82

Research works printed but not linked: 89

  1. [1]Saman R.A. Iqbal M. Nanotechnology-Based Drug Delivery Systems: Past, Present and Future Nanotechnology: Applications in Energy, Drug and Food Springer Berlin/Heidelberg, Germany 2019 175 185 10.1007/978-3-319-99602-8_7 · DOI
  2. [2]Kashkooli F.M. Soltani M. Souri M. Meaney C. Kohandel M. Nexus between in silico and in vivo models to enhance clinical translation of nanomedicine Nano Today 2021 36 101057 10.1016/j.nantod.2020.101057 · DOI · Paper page
  3. [3]Kashkooli F.M. Soltani M. Souri M. Controlled anti-cancer drug release through advanced nano-drug delivery systems: Static and dynamic targeting strategies J. Control. Release 2020 327 316 349 10.1016/j.jconrel.2020.08.012 32800878 · DOI · Paper page
  4. [4]Hassanzadeganroudsari M. Soltani M. Heydarinasab A. Apostolopoulos V. Akbarzadehkhiyavi A. Nurgali K. Targeted nano-drug delivery system for glioblastoma therapy: In vitro and in vivo study J. Drug Deliv. Sci. Technol. 2020 60 102039 10.1016/j.jddst.2020.102039 · DOI
  5. [5]Stylianopoulos T. Munn L.L. Jain R.K. Reengineering the Physical Microenvironment of Tumors to Improve Drug Delivery and Efficacy: From Mathematical Modeling to Bench to Bedside Trends Cancer 2018 4 292 319 10.1016/j.trecan.2018.02.005 29606314 PMC5930008 · DOI
  6. [7]Kashkooli F.M. Soltani M. Rezaeian M. Taatizadeh E. Hamedi M.-H. Image-based spatio-temporal model of drug delivery in a heterogeneous vasculature of a solid tumor—Computational approach Microvasc. Res. 2019 123 111 124 10.1016/j.mvr.2019.01.005 30711547 · DOI
  7. [8]Kashkooli F.M. Soltani M. Hamedi M.-H. Drug delivery to solid tumors with heterogeneous microvascular networks: Novel insights from image-based numerical modeling Eur. J. Pharm. Sci. 2020 151 105399 10.1016/j.ejps.2020.105399 32485347 · DOI
  8. [9]Lane L.A. Physics in nanomedicine: Phenomena governing the in vivo performance of nanoparticles Appl. Phys. Rev. 2020 7 011316 10.1063/1.5052455 · DOI
  9. [10]Wong C. Stylianopoulos T. Cui J. Martin J. Chauhan V.P. Jiang W. Popović Z. Jain R.K. Bawendi M.G. Fukumura D. Multistage nanoparticle delivery system for deep penetration into tumor tissue Proc. Natl. Acad. Sci. USA 2011 108 2426 2431 10.1073/pnas.1018382108 21245339 PMC3038705 · DOI
  10. [11]Kashkooli F.M. Soltani M. Momeni M.M. Rahmim A. Enhanced drug delivery to solid tumors via drug-loaded nanocarriers: An image-based computational framework Front. Oncol. 2021 in press PMC8264267 34249692
  11. [12]Saw W.S. Anasamy T. Foo Y.Y. Kwa Y.C. Kue C.S. Yeong C.H. Kiew L.V. Lee H.B. Chung L.Y. Delivery of Nanoconstructs in Cancer Therapy: Challenges and Therapeutic Opportunities Adv. Ther. 2021 4 2000206 10.1002/adtp.202000206 · DOI
  12. [13]Luo M. Feng Y. Wang T. Guan J. Micro-/Nanorobots at Work in Active Drug Delivery Adv. Funct. Mater. 2018 28 1706100 10.1002/adfm.201706100 · DOI
  13. [14]Hassanzadeh P. Atyabi F. Dinarvand R. The significance of artificial intelligence in drug delivery system design Adv. Drug Deliv. Rev. 2019 151–152 169 190 10.1016/j.addr.2019.05.001 31071378 · DOI
  14. [15]Tripathi R. Kumar A. Application of Nanorobotics for Cancer Treatment Mater. Today Proc. 2018 5 9114 9117 10.1016/j.matpr.2017.10.029 · DOI
  15. [17]Piroozmand F. Mohammadipanah F. Sajedi H. Spectrum of deep learning algorithms in drug discovery Chem. Biol. Drug Des. 2020 96 886 901 10.1111/cbdd.13674 33058458 · DOI
  16. [18]Thakur A. Mishra A.P. Panda B. Rodríguez D. Gaurav I. Majhi B. Application of artificial intelligence in pharmaceutical and biomedical studies Curr. Pharm. Des. 2020 26 3569 3578 10.2174/1381612826666200515131245 32410553 · DOI
  17. [19]Waheed A. Ashwin K. Assessing the Role of Artificial Intelligence in the Design of Drug Delivery Systems Int. J. Med. Sci. Diagn. Res. 2020 4 12 10.32553/ijmsdr.v4i12.725 · DOI
  18. [20]Sharma R. Singh D. Gaur P. Joshi D. Intelligent automated drug administration and therapy: Future of healthcare Drug Deliv. Transl. Res. 2021 1 25 10.1007/s13346-020-00876-4 33447941 · DOI
  19. [21]Ho D. Wang P. Kee T. Artificial intelligence in nanomedicine Nanoscale Horiz. 2019 4 365 377 10.1039/C8NH00233A 32254089 · DOI
  20. [22]Maroni A. Zema L. Del Curto M.D. Loreti G. Gazzaniga A. Oral pulsatile delivery: Rationale and chronopharmaceutical formulations Int. J. Pharm. 2010 398 1 8 10.1016/j.ijpharm.2010.07.026 20655998 · DOI
  21. [23]Staples M. Daniel K. Cima M.J. Langer R. Application of Micro- and Nano-Electromechanical Devices to Drug Delivery Pharm. Res. 2006 23 847 863 10.1007/s11095-006-9906-4 16715375 · DOI
  22. [24]Sutradhar K.B. Sumi C.D. Implantable microchip: The futuristic controlled drug delivery system Drug Deliv. 2014 23 1 11 10.3109/10717544.2014.903579 24758139 · DOI
  23. [25]Mobaraki M. Soltani M. Harofte S.Z. Zoudani E.L. Daliri R. Aghamirsalim M. Raahemifar K. Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review Pharmaceutics 2020 12 1232 10.3390/pharmaceutics12121232 33353013 PMC7765989 · DOI
  24. [26]Patel J. Patel A. Artificial Neural Networking in Controlled Drug Delivery Artificial Neural Network for Drug Design, Delivery and Disposition Academic Press Cambridge, MA, USA 2016 195 218 10.1016/b978-0-12-801559-9.00010-7 · DOI
  25. [27]Metwally A.A. Hathout R.M. Computer-Assisted Drug Formulation Design: Novel Approach in Drug Delivery Mol. Pharm. 2015 12 2800 2810 10.1021/mp500740d 26107396 · DOI
  26. [28]Petrović J. Ibrić S. Betz G. Parojčić J. Đurić Z. Application of dynamic neural networks in the modeling of drug release from polyethylene oxide matrix tablets Eur. J. Pharm. Sci. 2009 38 172 180 10.1016/j.ejps.2009.07.007 19632323 · DOI
  27. [29]Paixão P. Gouveia L. Morais J.A. Prediction of the in vitro intrinsic clearance determined in suspensions of human hepatocytes by using artificial neural networks Eur. J. Pharm. Sci. 2010 39 310 321 10.1016/j.ejps.2009.12.007 20056146 · DOI
  28. [30]Xu W.-J. Li N. Gao C.-K. Preparation of controlled porosity osmotic pump tablets for salvianolic acid and optimization of the formulation using an artificial neural network method Acta Pharm. Sin. B 2011 1 64 70 10.1016/j.apsb.2011.04.002 · DOI
  29. [31]Parojčić J. Ibrić S. Djurić Z. Jovanović M. Corrigan O.I. An investigation into the usefulness of generalized regression neural network analysis in the development of level A in vitro–in vivo correlation Eur. J. Pharm. Sci. 2007 30 264 272 10.1016/j.ejps.2006.11.010 17188851 · DOI
  30. [32]Specht D.F. A general regression neural network IEEE Trans. Neural Netw. 1991 2 568 576 10.1109/72.97934 18282872 · DOI
  31. [33]Davoudizadeh T. Sajjadi S.M. Ma’Mani L. Exhaustive investigation of drug delivery systems to achieve optimal condition of drug release using non-linear generalized artificial neural network method: Feedback from the loading step of drug J. Iran. Chem. Soc. 2018 15 1999 2006 10.1007/s13738-018-1397-9 · DOI
  32. [34]Boztepe C. Künkül A. Yüceer M. Application of artificial intelligence in modeling of the doxorubicin release behavior of pH and temperature responsive poly(NIPAAm-co-AAc)-PEG IPN hydrogel J. Drug Deliv. Sci. Technol. 2020 57 101603 10.1016/j.jddst.2020.101603 · DOI
  33. [35]Damiati S.A. Alaofi A.L. Dhar P. Alhakamy N.A. Novel machine learning application for prediction of membrane insertion potential of cell-penetrating peptides Int. J. Pharm. 2019 567 118453 10.1016/j.ijpharm.2019.118453 31233847 · DOI
  34. [36]Aroui S. Kenani A. Cell-Penetrating Peptides: A Challenge for Drug Delivery Cheminform. Its Appl. 2020 10.5772/intechopen.91684 · DOI
  35. [37]De Matas M. Shao Q. Biddiscombe M.F. Meah S. Chrystyn H. Usmani O.S. Predicting the clinical effect of a short acting bronchodilator in individual patients using artificial neural networks Eur. J. Pharm. Sci. 2010 41 707 715 10.1016/j.ejps.2010.09.018 20932900 · DOI
  36. [38]de Canete J.F. Gonzalez-Perez S. Ramos-Diaz J. Artificial neural networks for closed loop control of in silico and ad hoc type 1 diabetes Comput. Methods Programs Biomed. 2012 106 55 66 10.1016/j.cmpb.2011.11.006 22178070 · DOI
  37. [40]Ichimasa K. Kudo S.-E. Mori Y. Misawa M. Matsudaira S. Kouyama Y. Baba T. Hidaka E. Wakamura K. Hayashi T. Artificial intelligence may help in predicting the need for additional surgery after endoscopic resection of T1 colorectal cancer Endoscopy 2017 50 230 240 10.1055/s-0043-122385 29272905 · DOI
  38. [41]Kolisnyk T.Y. Ruban O.A. Fil N.Y. Kutsenko S.A. Application of an Artificial Neural Network for Design of Sustained-Release Matrix Tablets Containing Vaccinium Myrtillus Leaf Powder Extract Asian J. Pharm. 2018 12 2 10.22377/ajp.v12i02.2326 · DOI
  39. [42]Sedaghatkish A. Rezaeian M. Heydari H. Ranjbar A.M. Soltani M. Acoustic streaming and thermosensitive liposomes for drug delivery into hepatocellular carcinoma tumor adjacent to major hepatic veins; an acoustics–thermal–fluid-mass transport coupling model Int. J. Sci. 2020 158 106540 10.1016/j.ijthermalsci.2020.106540 · DOI
  40. [43]Tehrani M.H. Soltani M. Kashkooli F.M. Numerical simulation of synergistic interaction of magnetic hyperthermia and intraperitoneal delivery of temperature-sensitive liposomes Proceedings of the 2020 27th National and 5th International Iranian Conference on Biomedical Engineering (ICBME) Tehran, Iran 26–27 November 2020 1 6
  41. [44]Rezaeian M. Sedaghatkish A. Soltani M. Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy Drug Deliv. 2019 26 898 917 10.1080/10717544.2019.1660435 31526065 PMC6758722 · DOI
  42. [45]Jakupovic A. Kovacevic Z. Gurbeta L. Badnjevic A. Review of artificial neural network application in nanotechnology Proceedings of the 2018 7th Mediterranean Conference on Embedded Computing (MECO) Budva, Montenegro 10–14 June 2018 1 4
  43. [47]Khong J. Wang P. Gan T.R. Ng J. Anh T.T.L. Blasiak A. Kee T. Ho D. The role of artificial intelligence in scaling nanomedicine toward broad clinical impact Nanoparticles for Biomedical Applications Elsevier Amsterdam, The Netherlands 2020 385 407 10.1016/b978-0-12-816662-8.00022-9 · DOI
  44. [48]Rashid M.B.M.A. Toh T.B. Hooi L. Silva A. Zhang Y. Tan P.F. Teh A.L. Karnani N. Jha S. Ho C.-M. Optimizing drug combinations against multiple myeloma using a quadratic phenotypic optimization platform (QPOP) Sci. Transl. Med. 2018 10 eaan0941 10.1126/scitranslmed.aan0941 30089632 · DOI
  45. [49]Pantuck A.J. Lee D.K. Kee T. Wang P. Lakhotia S. Silverman M.H. Mathis C. Drakaki A. Belldegrun A.S. Ho C.M. Modulating BET bromodomain inhibitor ZEN-3694 and enzalutamide combination dosing in a metastatic prostate cancer patient using CURATE. AI, an artificial intelligence platform Adv. Ther. 2018 1 1800104 10.1002/adtp.201800104 · DOI
  46. [50]Wang H. Lee D.-K. Chen K.-Y. Chen J.-Y. Zhang K. Silva A. Ho C.-M. Ho D. Mechanism-Independent Optimization of Combinatorial Nanodiamond and Unmodified Drug Delivery Using a Phenotypically Driven Platform Technology ACS Nano 2015 9 3332 3344 10.1021/acsnano.5b00638 25689511 · DOI
  47. [51]Vamathevan J. Clark D. Czodrowski P. Dunham I. Ferran E. Lee G. Li B. Madabhushi A. Shah P. Spitzer M. Applications of machine learning in drug discovery and development Nat. Rev. Drug Discov. 2019 18 463 477 10.1038/s41573-019-0024-5 30976107 PMC6552674 · DOI · Paper page
  48. [52]Rana A. Yauney G. Lowe A. Shah P. Computational Histological Staining and Destaining of Prostate Core Biopsy RGB Images with Generative Adversarial Neural Networks Proceedings of the 2018 17th IEEE International Conference on Machine Learning and Applications (ICMLA) Orlando, FL, USA 17–20 December 2018 828 834
  49. [54]Xu Y. Hosny A. Zeleznik R. Parmar C. Coroller T. Franco I. Mak R.H. Aerts H.J. Deep Learning Predicts Lung Cancer Treatment Response from Serial Medical Imaging Clin. Cancer Res. 2019 25 3266 3275 10.1158/1078-0432.CCR-18-2495 31010833 PMC6548658 · DOI
  50. [56]Shah P. Kendall F. Khozin S. Goosen R. Hu J. Laramie J. Ringel M. Schork N. Artificial intelligence and machine learning in clinical development: A translational perspective NPJ Digit. Med. 2019 2 1 5 10.1038/s41746-019-0148-3 31372505 PMC6659652 · DOI
  51. [57]Maojo V. Martin-Sanchez F. Kulikowski C. Rodríguez-Patón A. Fritts M. Nanoinformatics and DNA-Based Computing: Catalyzing Nanomedicine Pediatr. Res. 2010 67 481 489 10.1203/PDR.0b013e3181d6245e 20118825 · DOI
  52. [58]Singh A.V. Laux P. Luch A. Sudrik C. Wiehr S. Wild A.-M. Santomauro G. Bill J. Sitti M. Review of emerging concepts in nanotoxicology: Opportunities and challenges for safer nanomaterial design Toxicol. Mech. Methods 2019 29 378 387 10.1080/15376516.2019.1566425 30636497 · DOI
  53. [59]Lammers T. Aime S. Hennink W.E. Storm G. Kiessling F. Theranostic Nanomedicine Acc. Chem. Res. 2011 44 1029 1038 10.1021/ar200019c 21545096 · DOI
  54. [60]Ha E. Basu N. Bose-O’Reilly S. Dórea J.G. McSorley E. Sakamoto M. Chan H.M. Current progress on understanding the impact of mercury on human health Environ. Res. 2017 152 419 433 10.1016/j.envres.2016.06.042 27444821 · DOI
  55. [61]Gehlenborg N. I O’Donoghue S. Baliga N.S. Goesmann A. A Hibbs M. Kitano H. Kohlbacher O. Neuweger H. Schneider R. Tenenbaum D. Visualization of omics data for systems biology Nat. Methods 2010 7 S56 S68 10.1038/nmeth.1436 20195258 · DOI
  56. [62]Fadeel B. Farcal L. Hardy B. Vázquez-Campos S. Hristozov D. Marcomini A. Lynch I. Valsami-Jones E. Alenius H. Savolainen K. Advanced tools for the safety assessment of nanomaterials Nat. Nanotechnol. 2018 13 537 543 10.1038/s41565-018-0185-0 29980781 · DOI
  57. [63]Puzyn T. Leszczynska D. Leszczynski J. Toward the development of “Nano-QSARs”: Advances and challenges Small 2009 5 2494 2509 10.1002/smll.200900179 19787675 · DOI
  58. [64]Puzyn T. Rasulev B. Gajewicz-Skretna A. Hu X. Dasari T.P. Michalkova A. Hwang H.-M. A Toropov A. Leszczynska D. Leszczynski J. Using nano-QSAR to predict the cytotoxicity of metal oxide nanoparticles Nat. Nanotechnol. 2011 6 175 178 10.1038/nnano.2011.10 21317892 · DOI
  59. [65]Winkler D.A. Role of Artificial Intelligence and Machine Learning in Nanosafety Small 2020 16 e2001883 10.1002/smll.202001883 32537842 · DOI
  60. [66]Fourches D. Pu D. Tassa C. Weissleder R. Shaw S.Y. Mumper R.J. Tropsha A. Quantitative Nanostructure−Activity Relationship Modeling ACS Nano 2010 4 5703 5712 10.1021/nn1013484 20857979 PMC2997621 · DOI
  61. [67]Jones D.E. Ghandehari H. Facelli J.C. A review of the applications of data mining and machine learning for the prediction of biomedical properties of nanoparticles Comput. Methods Programs Biomed. 2016 132 93 103 10.1016/j.cmpb.2016.04.025 27282231 PMC4902872 · DOI
  62. [68]Winkler D. Burden F. Yan B. Weissleder R. Tassa C. Shaw S. Epa V. Modelling and predicting the biological effects of nanomaterials Sar Qsar Environ. Res. 2014 25 161 172 10.1080/1062936X.2013.874367 24625316 · DOI
  63. [69]Lewinski N. Colvin V. Drezek R. Cytotoxicity of Nanoparticles Small 2008 4 26 49 10.1002/smll.200700595 18165959 · DOI
  64. [70]Stirling D.A. The Nanotechnology Revolution Nanotechnol. Revolut. 2018 281 434 10.1201/9781315110837 · DOI
  65. [71]Buzea C. Pacheco I.I. Robbie K. Nanomaterials and nanoparticles: Sources and toxicity Biointerphases 2007 2 MR17 MR71 10.1116/1.2815690 20419892 · DOI · Paper page
  66. [72]Uusitalo L.M. Hempel N. Recent Advances in Intracellular and In Vivo ROS Sensing: Focus on Nanoparticle and Nanotube Applications Int. J. Mol. Sci. 2012 13 10660 10679 10.3390/ijms130910660 23109815 PMC3472707 · DOI
  67. [73]Singh N. Manshian B. Jenkins G.J. Griffiths S.M. Williams P.M. Maffeis T.G. Wright C.J. Doak S.H. NanoGenotoxicology: The DNA damaging potential of engineered nanomaterials Biomaterials 2009 30 3891 3914 10.1016/j.biomaterials.2009.04.009 19427031 · DOI
  68. [74]Li J.J. Muralikrishnan S. Ng C.-T. Yung L.-Y.L. Bay B.-H. Nanoparticle-induced pulmonary toxicity Exp. Biol. Med. 2010 235 1025 1033 10.1258/ebm.2010.010021 20719818 · DOI
  69. [75]Kim J.A. Lee N. Kim B.H. Rhee W.J. Yoon S. Hyeon T. Park T.H. Enhancement of neurite outgrowth in PC12 cells by iron oxide nanoparticles Biomaterials 2011 32 2871 2877 10.1016/j.biomaterials.2011.01.019 21288566 · DOI
  70. [76]Horev-Azaria L. Baldi G. Beno D. Bonacchi D. Golla-Schindler U. Kirkpatrick J.C. Kolle S. Landsiedel R. Maimon O. Marche P.N. Predictive Toxicology of cobalt ferrite nanoparticles: Comparative in-vitro study of different cellular models using methods of knowledge discovery from data Part. Fibre Toxicol. 2013 10 32 10.1186/1743-8977-10-32 23895432 PMC3734223 · DOI
  71. [77]Wu J. Zhu Y.-J. Cao S.-W. Chen F. Hierachically Nanostructured Mesoporous Spheres of Calcium Silicate Hydrate: Surfactant-Free Sonochemical Synthesis and Drug-Delivery System with Ultrahigh Drug-Loading Capacity Adv. Mater. 2010 22 749 753 10.1002/adma.200903020 20217783 · DOI
  72. [78]Ribeiro C.A.S. De Castro C.E. Albuquerque L.J.C. Batista C.C.S. Giacomelli F.C. Biodegradable nanoparticles as nanomedicines: Are drug-loading content and release mechanism dictated by particle density? Colloid Polym. Sci. 2017 295 1271 1280 10.1007/s00396-016-4007-3 · DOI
  73. [79]Trucillo P. Campardelli R. Reverchon E. Supercritical CO2 assisted liposomes formation: Optimization of the lipidic layer for an efficient hydrophilic drug loading J. Co2 Util. 2017 18 181 188 10.1016/j.jcou.2017.02.001 · DOI
  74. [80]E Soliman M. Shalaby K.S. Casettari L. Bonacucina G. Cespi M. Palmieri G.F. A El Shamy A. A Sammour O. Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks Int. J. Nanomed. 2014 9 4953 4964 10.2147/IJN.S68737 PMC4211908 25364252 · DOI
  75. [81]Boso D.P. Ferrari M. Decuzzi P. A Schrefler B. Optimizing particle size for targeting diseased microvasculature: From experiments to artificial neural networks Int. J. Nanomed. 2011 6 1517 1526 10.2147/IJN.S20283 PMC3152469 21845041 · DOI
  76. [82]Bozuyuk U. Dogan N.O. Kizilel S. Deep Insight into PEGylation of Bioadhesive Chitosan Nanoparticles: Sensitivity Study for the Key Parameters Through Artificial Neural Network Model ACS Appl. Mater. Interfaces 2018 10 33945 33955 10.1021/acsami.8b11178 30212622 · DOI
  77. [83]Esmaeilzadeh-Gharehdaghi E. Faramarzi M.A. Amini M.A. Moazeni E. Amani A. Processing/formulation parameters determining dispersity of chitosan particles: An ANNs study J. Microencapsul. 2013 31 77 85 10.3109/02652048.2013.805842 23795904 · DOI
  78. [84]Youshia J. Ali M.E. Lamprecht A. Artificial neural network based particle size prediction of polymeric nanoparticles Eur. J. Pharm. Biopharm. 2017 119 333 342 10.1016/j.ejpb.2017.06.030 28694160 · DOI
  79. [85]Da Silva Luz G.V. Barros K.V.G. de Araújo F.V.C. da Silva G.B. da Silva P.A.F. Condori R.C.I. Mattos L. Nanorobotics in drug delivery systems for treatment of cancer: A review J. Mat. Sci. Eng. A 2016 6 167 180 10.17265/2161-6213/2016.5-6.005 · DOI
  80. [86]Mir U. Sharma S. Kar A.K. Gupta M.P. Critical success factors for integrating artificial intelligence and robotics Digit. PolicyRegul. Gov. 2020 22 307 331 10.1108/DPRG-03-2020-0032 · DOI
  81. [88]Saadeh Y. Vyas D. Nanorobotic Applications in Medicine: Current Proposals and Designs Am. J. Robot. Surg. 2014 1 4 11 10.1166/ajrs.2014.1010 26361635 PMC4562685 · DOI
  82. [89]Paul D. Sanap G. Shenoy S. Kalyane D. Kalia K. Tekade R.K. Artificial intelligence in drug discovery and development Drug Discov. Today 2021 26 80 93 10.1016/j.drudis.2020.10.010 33099022 PMC7577280 · DOI · Paper page
  83. [90]Modi D.P. Patel V.P. Patel R.B. Patel J.N. Bhimani B.V. Shah R.R. Nanorobots: The Emerging tools in Medicinal Applications. A Review Int. J. Drug Dev. Res. 2013 5 105 119
  84. [91]Hamet P. Tremblay J. Artificial intelligence in medicine Metabolism 2017 69 S36 S40 10.1016/j.metabol.2017.01.011 28126242 · DOI · Paper page
  85. [92]Fletcher M. Biglarbegian M. Neethirajan S. Intelligent system design for bionanorobots in drug delivery Cancer Nanotechnol. 2013 4 117 125 10.1007/s12645-013-0044-5 26069507 PMC4452041 · DOI
  86. [93]Soto F. Chrostowski R. Frontiers of Medical Micro/Nanorobotics: In vivo Applications and Commercialization Perspectives Toward Clinical Uses Front. Bioeng. Biotechnol. 2018 6 170 10.3389/fbioe.2018.00170 30488033 PMC6246686 · DOI
  87. [95]Frank M. Drikakis D. Charissis V. Machine-Learning Methods for Computational Science and Engineering Computation 2020 8 15 10.3390/computation8010015 · DOI
  88. [96]Kaushik A. Biomedical Nanotechnology Related Grand Challenges and Perspectives Front. Nanotechnol. 2019 1 1 10.3389/fnano.2019.00001 · DOI
  89. [97]Al Badi F.K. Alhosani K.A. Jabeen F. Stachowicz-Stanusch A. Shehzad N. Amann W. Challenges of AI Adoption in the UAE Healthcare Vis. J. Bus. Perspect. 2021 0972262920988398 10.1177/0972262920988398 · DOI

Authors
Soltani, M., Moradi Kashkooli, F., Souri, M., Zare Harofte, S., Harati, T., Khadem, A., Haeri Pour, M., & Raahemifar, K.
Affiliations
  • University of Waterloo (CA)
  • Department of Mechanical Engineering, K. N. Toosi University of Technology, Tehran 19967-15433, Iran
  • K. N. Toosi University of Technology (IR)
  • Pennsylvania State University (US)
Corresponding author
Soltani, Madjid
ORCID
Venue
Cancers
Publisher
MDPI AG
Published
2021-05-19
Volume
13
Issue
10
Pages
2481
ISSN
2072-6694 (ISSN-L)
DOI
10.3390/cancers13102481
PMC
PMC8161319
OpenAlex
W3163566284
Cited by
82
References
98
Citations by year
2026: 6 · 2025: 30 · 2024: 19 · 2023: 13 · 2022: 10 · 2021: 4
FWCI
0.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
  • Physical Sciences › Computer Science › Computational Theory and Mathematics › Computational Drug Discovery Methods
Keywords
nanoinformatics, nanomedicine, cancer therapy, artificial intelligence, nanorobots, targeted drug delivery, combination therapy, cancer diagnosis, drug toxicity, nanotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review